Skip to content

Clinical Performance of a Silicone Hydrogel Contact Lens Following Six Nights of Extended Wear

Clinical Performance of a Silicone Hydrogel Following Six Nights of Extended Wear

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03614130
Enrollment
22
Registered
2018-08-03
Start date
2018-08-23
Completion date
2018-09-11
Last updated
2021-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractive Errors

Keywords

Contact Lens, Extended Wear, Overnight Wear, Contralateral Wear, Vision Correction

Brief summary

The purpose of this clinical study is to evaluate the on-eye performance of an investigational soft contact lens compared to a commercially available soft contact lens following 1 week of extended wear.

Detailed description

Subjects will be randomized to wear the investigational contact lens in 1 eye and the commercially available contact lens in the other eye. Subjects will be expected to attend 3 scheduled study visits: Day 1 Baseline/Dispense; Day 2 Follow-up; and Week 1 Follow-up/Exit. The expected duration of exposure to each of the study lenses for all randomized, completed subjects was approximately 7 days / 6 nights of wear.

Interventions

Investigational silicone hydrogel contact lens

Commercially available silicone hydrogel contact lens

Sponsors

Alcon Research
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Intervention model description

In this contralateral study, subjects will be randomized to wear the investigational lens in 1 eye and the control lens in the other eye.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Key Inclusion Criteria: * Able to understand and sign an Institutional Review Board/Ethics Committee-approved Informed Consent form. * Successful wear of spherical soft contact lenses in both eyes during the past 3 months for a minimum of 5 days per week and in an extended wear modality a minimum of 1 night per week. * Best Corrected Visual Acuity (BCVA) of 20/25 or better in each eye. * Other protocol-specified inclusion criteria may apply. Key

Exclusion criteria

* Any condition, use of medications, or surgery that could contraindicate contact lens wear, as determined by the Investigator. * Current Biofinity© lens wearer. * Pregnant or breast-feeding. * Other protocol-specified

Design outcomes

Primary

MeasureTime frameDescription
Visual Acuity (VA) With Study Lenses, Collected by EyeDay 1 Dispense; Day 2 Follow-up (ideally within 4 hours of awakening); Week 1 Follow-up/ExitVisual acuity (VA) was assessed for each eye individually with study lenses in place using a letter chart. VA was collected in Snellen and converted to logarithm minimum angle of resolution (logMAR). A logMAR value of 0 equates to 20/20 Snellen visual acuity (normal distance eyesight), with a lower logMAR value indicating better visual acuity. No formal hypothesis testing was planned.

Countries

United States

Participant flow

Recruitment details

Subjects were recruited from 2 investigative sites located in the United States.

Pre-assignment details

This reporting group includes all enrolled subjects.

Participants by arm

ArmCount
LID011121 (OD) / Biofinity (OS)
LID011121 contact lens worn in the right eye, with comfilcon A contact lens worn in the left eye, as randomized, for approximately 6 nights of extended (overnight) wear
10
Biofinity (OD) / LID011121 (OS)
Comfilcon A contact lens worn in the right eye, with LID011121 contact lens worn in the left eye, as randomized, for approximately 6 nights of extended (overnight) wear
12
Total22

Baseline characteristics

CharacteristicLID011121 (OD) / Biofinity (OS)TotalBiofinity (OD) / LID011121 (OS)
Age, Continuous43.8 years
STANDARD_DEVIATION 7.7
40.8 years
STANDARD_DEVIATION 9.5
38.3 years
STANDARD_DEVIATION 10.3
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants1 Participants1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
9 Participants20 Participants11 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants1 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants1 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
2 Participants3 Participants1 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants1 Participants1 Participants
Race (NIH/OMB)
White
7 Participants17 Participants10 Participants
Region of Enrollment
United States
10 participants22 participants12 participants
Sex: Female, Male
Female
6 Participants12 Participants6 Participants
Sex: Female, Male
Male
4 Participants10 Participants6 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 220 / 220 / 220 / 22
other
Total, other adverse events
0 / 220 / 220 / 220 / 22
serious
Total, serious adverse events
0 / 220 / 220 / 220 / 22

Outcome results

Primary

Visual Acuity (VA) With Study Lenses, Collected by Eye

Visual acuity (VA) was assessed for each eye individually with study lenses in place using a letter chart. VA was collected in Snellen and converted to logarithm minimum angle of resolution (logMAR). A logMAR value of 0 equates to 20/20 Snellen visual acuity (normal distance eyesight), with a lower logMAR value indicating better visual acuity. No formal hypothesis testing was planned.

Time frame: Day 1 Dispense; Day 2 Follow-up (ideally within 4 hours of awakening); Week 1 Follow-up/Exit

Population: Safety Analysis Set

ArmMeasureGroupValue (MEAN)Dispersion
LID011121Visual Acuity (VA) With Study Lenses, Collected by EyeWeek 1 Follow-up/Exit-0.06 logMARStandard Deviation 0.07
LID011121Visual Acuity (VA) With Study Lenses, Collected by EyeDay 1 Dispense-0.04 logMARStandard Deviation 0.06
LID011121Visual Acuity (VA) With Study Lenses, Collected by EyeDay 2 Follow-up-0.06 logMARStandard Deviation 0.11
BiofinityVisual Acuity (VA) With Study Lenses, Collected by EyeDay 2 Follow-up-0.09 logMARStandard Deviation 0.06
BiofinityVisual Acuity (VA) With Study Lenses, Collected by EyeDay 1 Dispense-0.06 logMARStandard Deviation 0.06
BiofinityVisual Acuity (VA) With Study Lenses, Collected by EyeWeek 1 Follow-up/Exit-0.08 logMARStandard Deviation 0.06

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026